Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025GlobeNewsWire • 04/15/25
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical CancerGlobeNewsWire • 03/31/25
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical CancerBenzinga • 03/27/25
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after ChemotherapyGlobeNewsWire • 03/27/25
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.GlobeNewsWire • 03/22/25
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian CancerBusiness Wire • 03/17/25
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 03/12/25
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular LymphomaGlobeNewsWire • 02/20/25
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care ConferenceGlobeNewsWire • 02/19/25
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 12/09/24